Latest news with #DavosPharma
Business Standard
21-07-2025
- Business
- Business Standard
Anthem Biosciences jumps on debut
Shares of Anthem Biosciences were currently trading at Rs 726.35 at 10:21 IST on the BSE, representing a premium of 27.43% compared with the issue price of Rs 570. The scrip was listed at Rs 723.10, exhibiting a premium of 26.86% to the issue price. So far, the stock has hit a high of Rs 746.70 and a low of Rs 723.05. On the BSE, over 25.90 lakh shares of the company were traded in the counter so far. The initial public offer of Anthem Biosciences was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
17-07-2025
- Business
- Business Standard
Anthem Biosciences IPO ends with 63.86x subscription
The offer received bids for 281.45 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,45,24,128 shares as against 4,40,70,682 shares on offer. The issue was subscribed 63.86 times. The Qualified Institutional Buyers (QIBs) category was subscribed 182.65 times. The Non-Institutional Investors (NIIs) category was subscribed 42.36 times. The Retail Individual Investors (RIIs) category was subscribed 5.64 times. The issue opened for bidding on 14 July 2025 and it closed on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
16-07-2025
- Business
- Business Standard
Anthem Biosciences IPO subscribed 63.86 times
The offer received bids for 281.44 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 2,81,44,34,740 shares as against 4,40,70,682 shares on offer, according to stock exchange data at 17:30 IST on Wednesday (16 July 2025). The issue was subscribed 63.86 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
15-07-2025
- Business
- Business Standard
Anthem Biosciences IPO subscribed 3.28 times
The offer received bids for 14.47 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 14,47,66,596 shares as against 4,40,70,682 shares on offer, according to stock exchange data at 17:00 IST on Tuesday (15 July 2025). The issue was subscribed 3.28 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 5,95,61,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 43,17,47,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
Business Standard
14-07-2025
- Business
- Business Standard
Anthem Biosciences IPO subscribed 73%
The offer received bids for 3.21 crore shares as against 4.40 crore shares on offer. The initial public offer of Anthem Biosciences received bids for 32,113,406 shares as against 44,070,682 shares on offer, according to stock exchange data at 17:00 IST on Monday (14 July 2025). The issue was subscribed 0.73 times. The issue opened for bidding on 14 July 2025 and it will close on 16 July 2025. The price band of the IPO is fixed between Rs 540 and 570 per share. An investor can bid for a minimum of 26 equity shares and in multiples thereof. The IPO is a full offer for sale of 59,561,404 equity shares at the upper price, amounting to Rs 3,395 crore. The company will not receive any funds from the offer; all proceeds will go to the selling shareholders based on the shares they offered. The promoters and promoter group hold a total of 431,747,949 equity shares, making up 76.87% of the pre-offer issued and paid-up equity share capital. Their shareholding after the IPO is expected to be around 74.69%. Anthem Biosciences is a tech-oriented CRDMO, providing drug discovery and manufacturing services, as well as specialty ingredients like probiotics, enzymes, and peptides. In FY25, CRDMO contributed 81.65% of its revenue. It serves over 550 clients in more than 44 countries, with Europe and North America being key markets. Supported by green chemistry and a partnership with Davos Pharma in the U.S., the company is growing its capacity and working on technologies like RNAi and ADCs. Ahead of the IPO, Anthem Biosciences on Friday, 11 July 2025, raised Rs 1,016.02 crore from anchor investors. The board allotted 1.78 crore shares at Rs 570 each to 60 anchor investors. The firm reported a consolidated net profit of Rs 451.26 crore and sales of Rs 1,844.55 crore for the twelve months ended on 31 March 2025.
